Astellas/Cardiome's Vernakalant Wins Advisory Committee Approval In 6-2 Vote
This article was originally published in PharmAsia News
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee voted to approve Astellas Pharma/Cardiome's new drug application for its antiarrhythmic Kynapid (vernakalant hydrochloride injection) Dec. 11